BMO reiterates Allstate stock Outperform on New York insurance reforms

BMO reiterated an Outperform rating on Allstate (ALL) with a $249 price target, roughly in line with the stock at $249.94 and near the 52-week high of $257.67. New York insurance reforms are estimated to reduce auto-insurance revenue growth drag by 45bps to organic policy growth and support profit margins, lifting auto organic growth from negative in 2024 to +5% by 2027. Offsetting factors include $289M catastrophe losses in May and an HSBC downgrade to Hold (price target raised to $264).

Analysis

The real mechanism here is margin repair, not a step-change in growth. For a capital-light insurer trading at roughly 5.5x earnings, even a modest lift in loss ratio economics can matter more than headline policy counts, but the market is already close to that math: the stock is near a 52-week high and near published fair value, which limits multiple expansion unless the next few quarters show cleaner underwriting and fewer catastrophe offsets.

Second-order, the New York reform benefit is more asymmetric for carriers with a large, low-quality book there; that argues for ALL relative to broader auto peers, but not necessarily for an outright chase. PGR remains the cleaner growth compounder, so the spread trade is really about whether the market pays up for growth or re-rates value on visible margin improvement. If reforms bring more capacity back into the state, some of ALL’s benefit may be competed away over 6-18 months, capping the structural upside.

Near term, the main risk is that catastrophe volatility overwhelms the reform narrative; large loss months can swamp the incremental state-policy tailwind and delay any rerating. The catalyst path is slower than the headline suggests: next 1-3 months should be driven by reserve/cat-loss disclosures and whether NY auto profitability actually inflects, while the 2027 organic growth target is too far out to anchor the stock today. The consensus may be overestimating how much of the reform gain can be monetized while ALL is still shrinking exposure in the state.

Key Decisions for Investors

• Do not chase ALL at current levels; treat it as a hold/trim candidate unless you get a 5-8% pullback or confirmation of improving combined ratio in the next earnings cycle.
• Relative value: long ALL / short PGR on a 3-6 month horizon if you expect value-style re-rating in P&C; target a 5-10% spread move, stop if PGR continues to outperform on growth and margin stability.
• Add to ALL only after the next catastrophe update or quarterly filing confirms that New York reform is translating into lower loss ratios without reserve noise; this is a fundamentals-confirmation trade, not a momentum chase.
• Watch for a thesis break if catastrophe losses stay elevated into the next quarter or if management tones down the 2027 organic growth bridge; either would cap the re-rate and justify de-risking.
• No direct action in BAC/HSBC from this note; the sector read-through is too indirect to justify a standalone bank trade.